About us
Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) is pioneering the development and commercialisation of a New Class of Synthetic Anti-Infectives designed to address the urgent global health threat posed by antibiotic resistant superbugs and emerging viral pathogens.
Recce’s anti-infective pipeline is comprised of broad-spectrum synthetic antibiotics, RECCE® 327 and RECCE® 435, and a synthetic anti-viral, RECCE® 529. Recce’s compounds, respectively, contain unique mechanisms of action against hypermutation on bacteria and viruses.
read more..
